Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

538.000
+5.0000.94%
Volume:561.82K
Turnover:301.87M
Market Cap:128.58B
PE:-278.34
High:545.000
Open:541.500
Low:527.500
Close:533.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.80
T/O Rate:0.32%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.933
ROE:2.92%
ROA:0.03%
PB:20.65
PE(LYR):-278.34
PS:52.84

Loading ...

Movement Alert|Kelun-Biotech Rises 7.18% in Regular Trading, ASCO Landmark Data Continues to Drive Momentum Alongside Sector Rally

Market Focus
·
Jun 29

Movement Alert|Kelun-Biotech Falls 3.08% in Regular Trading, Trading at 411.4 HKD

Market Focus
·
Jun 25

Movement Alert|Kelun-Biotech Rises 7.44% in Regular Trading, ASCO Phase III Lung Cancer Data Catalyzes Overseas Commercialization Expectations

Market Focus
·
Jun 24

SKB BIO Shares Surge Over 6% on Key ASCO Lung Cancer Data, sac-TMT Nears Global Commercialization

Stock News
·
Jun 24

Movement Alert|Kelun-Biotech Rises 3.16% in Regular Trading, Biotech Sector Broadly Rallies Amid Positive Analyst Coverage

Market Focus
·
Jun 23

Kelun-Biotech says Phase III trial tests sac-TMT plus osimertinib in first-line EGFR-mutant NSCLC

Reuters
·
Jun 22

Movement Alert|Kelun-Biotech Falls 3.7% in Regular Trading, Biotech Sector Broadly Under Pressure

Market Focus
·
Jun 22

Industrial Securities Initiates Coverage on SKB BIO with "Overweight" Rating Following Key ASCO Lung Cancer Data Release

Stock News
·
Jun 18

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, RMB 703 Million Settlement Payment from Yilian Bio Continues to Catalyze

Market Focus
·
Jun 15

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink

MT Newswires Live
·
Jun 12

Movement Alert|Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical

Market Focus
·
Jun 12

SKB BIO Receives Settlement Payment from Yilian Biopharma

Stock News
·
Jun 12

Sichuan Kelun-Biotech Biopharmaceutical Co - Receives RMB602.5 Mln From Medilink Therapeutics for Out-Licensing of Yl201

THOMSON REUTERS
·
Jun 12

Movement Alert|Kelun-Biotech Falls 3.34% in Regular Trading, Biotech Sector Broadly Weakens Amid Ongoing Chairman Sell-Off Pressure

Market Focus
·
Jun 11

Hong Kong Stocks Show Movement: Super-Long-Acting Anti-TSLP Antibody Phase II Trial Completes First Dosing; HBM Holdings-B and SKB BIO Both Surge Over 5% During Session

Stock News
·
Jun 10

Movement Alert|Kelun-Biotech Rises 3.25% in Regular Trading, Multiple Brokerages Maintain Buy Ratings as ASCO Data Continues to Catalyze

Market Focus
·
Jun 10

Kelun-Biotech says partner Windward Bio doses first patients in Phase 2 COPD trial of SKB378/WIN378

Reuters
·
Jun 09

Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 Sirius Copd Study of Skb378/Win378

THOMSON REUTERS
·
Jun 09

A Look At Sichuan Kelun-Biotech Biopharmaceutical’s (SEHK:6990) Valuation After Positive 2026 ASCO Lung Cancer Data

Simply Wall St.
·
Jun 08